Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.53 -0.12 (-7.26%)
As of: Oct 1, 2026 · 3:59 PM EDT

Transcode Therapeutics (RNAZ) Non-Current Deferred Tax Liability (2025 - 2026)

Updated

Transcode Therapeutics (RNAZ) reported Non-Current Deferred Tax Liability of $457,677 for Q2 2026, up 0.1% from the prior quarter.

Analysis

Transcode Therapeutics (RNAZ) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends

At the end of FY2025, Transcode Therapeutics posted Non-Current Deferred Tax Liability of $226,068.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Transcode Therapeutics 1.70 Mn 1.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 457,677.00
Mar 31, 2026 457,377.00
Dec 31, 2025 226,068.00
API Access

Transcode Therapeutics Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=RNAZ&period=max&api_key=YOUR_API_KEY